 | John GiblinFrom the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
John Giblin:Expert Impact
Concepts for whichJohn Giblinhas direct influence:Lisdexamfetamine dimesylate,Oros methylphenidate,Ldx adults,Lisdexamfetamine dimesylate ldx,Crossover study,Lisdexamfetamine dimesylate adults,Adults adhd,Hyperactivity disorder.
John Giblin:KOL impact
Concepts related to the work of other authors for whichfor which John Giblin has influence:Lisdexamfetamine dimesylate,Hyperactivity disorder,Adults adhd,Attention deficit,Children adolescents,School performance,College students.
KOL Resume for John Giblin
| Year | |
|---|---|
| 2012 | From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Centers, LLC, Little Rock, AR; ∥Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV; ¶Biostatistics, US Medical; and #Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ. |
| 2011 | Clinical Study Centers, LLC, Little Rock, AK, USA |
| 2010 | Clinical Study Centers, LLC, Little Rock, AR, USA |
| Concept | World rank |
|---|---|
| postdose sessions | #5 |
| week ldx | #5 |
| attemptedcorrect | #6 |
| ldx permp scores | #6 |
| crossover phase adults | #6 |
| permp scores placebo | #6 |
| phase lisdexamfetamine | #7 |
| assess lisdexamfetamine | #7 |
| aima improvement | #7 |
| 5 ldx | #7 |
| doseoptimization phase | #7 |
| doseoptimization phase quality | #7 |
| participants doseoptimization phase | #7 |
| 4 lisdexamfetamine | #7 |
| dimesylate adult | #7 |
| life improvements adults | #7 |
| hours permp | #8 |
| permp assessments remission | #8 |
| safety assessments teaes | #8 |
| postdose sizes | #8 |
| openlabel doseoptimization | #8 |
| 20 child cross | #8 |
| 20 dexmethylphenidate | #8 |
| fourth editiondiagnosed adhd | #8 |
| adult prompts remission | #8 |
| adults awe | #8 |
| crossover week ldx | #8 |
| ldx teaes | #8 |
| 017 remission | #8 |
| permp assessments | #8 |
| sizes 14 hours | #8 |
| 016 permp | #8 |
| adhd impact module | #8 |
| prompts remission | #8 |
| ldx 4 | #8 |
| awe ldx | #8 |
| permpa | #8 |
| avg 1012 | #8 |
| sizes permpa | #8 |
| ldx awe | #8 |
| size awe | #8 |
| assessed permp | #8 |
| permpcorrect scores | #8 |
| 20 dmpher | #8 |
| permp 08 | #8 |
| lisdexamfetamine dimesylate awe | #8 |
| awe medium | #8 |
| corrected skamp | #8 |
| 017 permp | #8 |
| dmpher 20 | #9 |
Prominent publications by John Giblin
BACKGROUND: Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment.
METHODS: After open-label dose optimization (4-week) with LDX, 30-70 mg/d, subjects entered a 2-week randomized, double-blind, placebo-controlled crossover phase. Efficacy assessments included the Permanent Product Measure of Performance (PERMP) total score ...
| Known for Lisdexamfetamine Dimesylate | Ldx Adults | Hyperactivity Disorder | Crossover Study | Workplace Environment |
A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder
[ PUBLICATION ]
Background: Long-acting methylphenidate formulations provide control of attention-deficit hyperactivity disorder (ADHD) symptoms for up to 12 hours; however, not all formulations have rapid onset of therapeutic effect, which is essential for providing symptom control during morning hours. The primary objective of this randomized, double-blind, crossover study was to assess the efficacy of dexmethylphenidate extended release (ER) versus placebo by measuring the change from pre-dose to 0.5 ...
| Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose | Laboratory Classroom |
Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
[ PUBLICATION ]
OBJECTIVE: To examine duration of efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder (ADHD) by effect size in performance and symptom improvement in a simulated adult workplace environment (AWE).
METHODS: Adults (aged 18-55 years) with ADHD enrolled in the AWE study of LDX with open-label dose-optimization and randomized, placebo-controlled, double-blind, 2-way crossover phases. Efficacy measures included the Permanent Product Measure of ...
| Known for Lisdexamfetamine Dimesylate | Hyperactivity Disorder | Adults Adhd | Adult Attention | Efficacy Measures |
Effects of Open-Label Lisdexamfetamine Dimesylate on Self-Reported Quality of Life in Adults with ADHD
[ PUBLICATION ]
OBJECTIVE: To assess improvements in quality of life measurements during the open-label portion of a trial examining duration of efficacy of lisdexamfetamine dimesylate in a simulated adult workplace environment.
METHODS: A 4-week, open-label, dose-optimization phase followed by a randomized, double-blind, multicenter, placebo-controlled, 2-way crossover phase to evaluate safety and efficacy of lisdexamfetamine dimesylate in the adult workplace environment was conducted. Clinical ...
| Known for Lisdexamfetamine Dimesylate | Life Adults | Reported Quality | Attention Deficit | Disorder Hyperactivity |
OBJECTIVE: To assess effects of OROS methylphenidate on cognitive and academic tasks in 9 to 12 year olds with attention-deficit/hyperactivity disorder (ADHD).
METHODS: A double-blind, within-subject, crossover design was used to compare OROS methylphenidate with placebo in a laboratory classroom setting on several cognitive and academic tasks for 68 children who met randomization criteria.
RESULTS: Performance on the following measures was significantly better when children received ...
| Known for Oros Methylphenidate | Cognitive Tasks | Hyperactivity Disorder | Attention Deficit | Adhd Symptoms |
The objective of this study was to evaluate the safety and efficacy of dexmethylphenidate extended-release (d-MPH-ER) 30 versus 20 mg in children with attention-deficit/hyperactivity disorder (ADHD) in a 12-hour laboratory classroom setting. In a randomized, double-blind, 3-period × 3-treatment, crossover study, children aged 6 to 12 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-diagnosed ADHD previously stabilized on MPH (40-60 mg/d) or D-MPH (20-30 ...
| Known for Hyperactivity Disorder | 30 Mph | Versus 20 | Attention Deficit | 165 Children |
Background and Objective: The primary objective of this study was to characterize the pharmacokinetic profile of pantoprazole delayed-release granules in infants and children aged 1 month to <6 years with gastro-oesophageal reflux disease (GORD). The studies described in this manuscript were conducted to fulfil the requirements of the paediatric written request for pantoprazole by the US FDA.Methods: Two randomized, open-label, multicentre studies were conducted in infants aged 1 month ...
| Known for Reflux Disease | Infants Children | Proton Pump | Gastro Oesophageal | 12 Months |
